Updates

Clinigen - Acquisition anticipated in March

March 2013

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Clinigen shot ahead to a new high after its H1 results came in 33% ahead of expectations with sales up 86% to Â£61m and pretax profit up 54% at Â£9.7m. Net cash was Â£22.3m. The out performance was driven by CTS, which supplies drugs to meet clinical trial needs and increased its sales by 113% to Â£45.1m, helped by some big contracts for sourcing anti-viral studies (into hepatitis B and HIV) in the US. These added Â£24m sales but at this order level were inherently lower margin. The contracts are mostly complete but chief exec Peter George points to other similar work coming down the pipe including supplying biosimilars comparator drugs for 20 of the 35 key biological drugs coming off patent in the next few years.The smalle ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Optimal Payments - Three states legalise online gaming

Tracsis - Market awaits the next aquisition

Clinigen (November 2016)

Clinigen (October 2016)

Clinigen (October 2015)

Clinigen (August 2015)

Clinigen - Completes £225m Idis acquisition (June 2015)

Clinigen (April 2015)

Clinigen (February 2015)

Clinigen - Acquires speciality products (September 2014)

Clinigen - Company reassures investors with trading update (August 2014)

Clinigen (March 2014)

Clinigen - Growing rapidly into valuation (February 2014)

Clinigen - On lookout for 3-5 more deals (November 2013)

Clinigen - Another upgrade to forecast (September 2013)

Clinigen - First of half a dozen deals (April 2013)

Clinigen - Trial services to grow at 17% annual clip (December 2012)

Clinigen - New issue growing like topsy (November 2012)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X